All companies
Visit website
Biomedican inc
OperatingBioMedican, Inc
Founded 2017
Producing pharmaceutical-grade cannabinoids at 70-90% lower cost via biosynthesis
Post-money valuation ⓘ
$56.6M
As of Oct 2021 · from Biomedican Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$220,467
Across 1 round since 2021
Latest share price
$4.50
Biomedican Preferred Stock 1 offering price
Financials
FY2019–FY2021 · from SEC filings · hover any figure for its source$0
−$971K
2019
$0
−$971K
2020
$0
−$1.6M
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$971,290
-$971,290
-$1,646,200
Taxes paid
$0
$0
$0
Balance sheet
Cash
$134,712
$134,712
$19,099
Accounts receivable
$0
$0
$0
Total assets
$222,406
$222,406
$138,963
Short-term debt
$167,073
$167,073
$510,970
Long-term debt
$318,396
$318,396
$9,160
Total liabilities
$485,469
$485,469
$520,130
Other
Headcount
—
9
6
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$56.6M
post-money
Biomedican Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $220.5K / $1.1MInvestors 167Post-money $56.6M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 5 annual reports (FY2021–FY2025)
167 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001865730Share price $4.50
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.